DNA Damage Repair in Brain Tumor Immunotherapy
- PMID: 35095931
- PMCID: PMC8792754
- DOI: 10.3389/fimmu.2021.829268
DNA Damage Repair in Brain Tumor Immunotherapy
Abstract
With the gradual understanding of tumor development, many tumor therapies have been invented and applied in clinical work, and immunotherapy has been widely concerned as an emerging hot topic in the last decade. It is worth noting that immunotherapy is nowadays applied under too harsh conditions, and many tumors are defined as "cold tumors" that are not sensitive to immunotherapy, and brain tumors are typical of them. However, there is much evidence that suggests a link between DNA damage repair mechanisms and immunotherapy. This may be a breakthrough for the application of immunotherapy in brain tumors. Therefore, in this review, first, we will describe the common pathways of DNA damage repair. Second, we will focus on immunotherapy and analyze the mechanisms of DNA damage repair involved in the immune process. Third, we will review biomarkers that have been or may be used to evaluate immunotherapy for brain tumors, such as TAMs, RPA, and other molecules that may provide a precursor assessment for the rational implementation of immunotherapy for brain tumors. Finally, we will discuss the rational combination of immunotherapy with other therapeutic approaches that have an impact on the DNA damage repair process in order to open new pathways for the application of immunotherapy in brain tumors, to maximize the effect of immunotherapy on DNA damage repair mechanisms, and to provide ideas and guidance for immunotherapy in brain tumors.
Keywords: DNA damage repair; ICI; TAMs; TME; biomarker; brain tumor; combination therapy; immunotherapy.
Copyright © 2022 Zhao, Xu, Ma, Chen, Jiang, Cai and Meng.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Immunotherapy in gliomas: Are we reckoning without the innate immunity?Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419843378. doi: 10.1177/2058738419843378. Int J Immunopathol Pharmacol. 2019. PMID: 30968718 Free PMC article. Review.
-
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.Eur Urol. 2019 Mar;75(3):435-444. doi: 10.1016/j.eururo.2018.09.022. Epub 2018 Sep 28. Eur Urol. 2019. PMID: 30274701 Free PMC article. Review.
-
DNA Damage and Repair Biomarkers of Immunotherapy Response.Cancer Discov. 2017 Jul;7(7):675-693. doi: 10.1158/2159-8290.CD-17-0226. Epub 2017 Jun 19. Cancer Discov. 2017. PMID: 28630051 Free PMC article. Review.
-
Targeting tumor-associated macrophages for cancer immunotherapy.Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188434. doi: 10.1016/j.bbcan.2020.188434. Epub 2020 Sep 18. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32956767 Review.
-
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Curr Treat Options Oncol. 2017. PMID: 28785997 Review.
Cited by
-
Radioresistance in brain tumors: Strategies for improved radiotherapy outcomes.Brain Spine. 2024 Aug 6;4:102912. doi: 10.1016/j.bas.2024.102912. eCollection 2024. Brain Spine. 2024. PMID: 39247725 Free PMC article. No abstract available.
-
A Streamlined Diagnostic Process Improved the Outcomes of Patients with Adult-Onset Still's Disease: A Single-Center Retrospective Observational Study.Rheumatol Ther. 2023 Apr;10(2):343-355. doi: 10.1007/s40744-022-00516-y. Epub 2022 Dec 10. Rheumatol Ther. 2023. PMID: 36495404 Free PMC article.
-
Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance.Genes (Basel). 2023 Dec 17;14(12):2227. doi: 10.3390/genes14122227. Genes (Basel). 2023. PMID: 38137049 Free PMC article.
References
-
- Scarbrough PM, Weber RP, Iversen ES, Brhane Y, Amos CI, Kraft P, et al. . A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Cancer Epidemiol Biomarkers Prev (2016) 25(1):193–200. doi: 10.1158/1055-9965.EPI-15-0649 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical